Target intelligence / Profile preview

Ileal bile acid-binding protein (FABP6) (FABP6)

Target
FABP6
Molecular classification
Fatty acid-binding protein family, Intracellular lipid-binding protein family, Calycin superfamily
01

Overview

Ileal bile acid-binding protein (FABP6), also known as gastrotropin, is a member of the intracellular lipid-binding protein (iLBP) family specifically expressed in the villi of the distal ileum (UniProt P51161). Its primary biological role is the high-affinity binding and intracellular transport of bile acids, facilitating their movement from the apical sodium-dependent bile acid transporter (ASBT) to the basolateral membrane for secretion into the portal circulation (PubMed: 25533013). FABP6 is a key component of the enterohepatic circulation and acts as a metabolic sensor by delivering bile acids to the farnesoid X receptor (FXR), which regulates bile acid synthesis and glucose homeostasis (PubMed: 12663518). In clinical contexts, FABP6 is frequently overexpressed in colorectal adenomas and carcinomas, suggesting a role in promoting cell proliferation and survival in response to high bile acid levels (PubMed: 16331255). Consequently, it is investigated as both a biomarker for early-stage colorectal cancer and a therapeutic target for metabolic syndromes and cholestatic liver diseases. Research into FABP6 inhibitors aims to disrupt the reabsorption of bile acids to lower systemic levels and modulate metabolic pathways. The protein's unique expression pattern and specific ligand binding make it an attractive site for tissue-specific pharmacological intervention.

Other names
GastrotropinFatty acid-binding protein 6I-BABPILBPI-BALPIleal lipid-binding protein
02

Mechanism of action

Inhibition of intracellular bile acid transport and modulation of FXR-mediated gene expression (PubMed: 25533013, 12663518).

03

Biological functions

Bile acid transportLipid metabolismEnterohepatic circulationRegulation of FXR signaling
04

Disease associations

Colorectal cancerMetabolic syndromeType 2 diabetesNonalcoholic steatohepatitis (NASH)Gallstone diseaseBile acid malabsorption
05

Safety considerations

Bile acid malabsorptionDiarrheaPotential interference with fat-soluble vitamin absorptionAlteration of gut microbiome
06

Interacting drugs

Cholic acid

4 more in the full profile.

07

Biomarkers

FABP6 mRNA expressionSerum bile acid concentrationsFecal bile acid levelsSerum 7α-hydroxy-4-cholesten-3-one (C4)

Beyond the preview

Go deeper on Ileal bile acid-binding protein (FABP6) (FABP6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ileal bile acid-binding protein (FABP6) (FABP6).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call